清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

医学 内科学 移植 胃肠病学 胆红素 肝移植 丙氨酸转氨酶 造血干细胞移植 血栓性微血管病 天冬氨酸转氨酶 队列 门静脉血栓形成 肝静脉闭塞性疾病 外科 血栓形成 疾病 生物 生物化学 酶 碱性磷酸酶
作者
Thomas Luft,Hao Dai,Aleksandar Radujkovic,David Schult,Joshua Majer-Lauterbach,Olga Blau,Lars Bullinger,Sihe Jiang,Carsten Müller‐Tidow,Peter Dreger,Olaf Penack
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 4487-4487
标识
DOI:10.1182/blood-2019-124284
摘要

Background: Hyperbilirubinemia occurs frequently in the early phase after allogeneic stem cell transplantation (alloSCT). In the present study we analysed whether high bilirubin levels until day +28 after alloSCT are associated with clinical outcome independent of liver toxicity and clinically defined diseases, such as sinusoidal obstruction syndrome (SOS/VOD), transplantation-associated thrombotic microangiopathy (TAM) or steroid-refractory acute graft-versus-host disease (refrGVHD). Methods: Serum bilirubin levels from 901 patients (training cohort) and from 399 patients transplanted in an independent institution (validation cohort), obtained over the first 4 weeks following alloSCT, were analyzed along with routine serum markers for liver cell and cholangiocyte damage (alanine transaminase, ALT, gamma-glutamyltransferase, gGT), and with markers of endothelial dysfunction, such as Angiopoietin-2 serum levels and the endothelial activation and stress index before conditioning therapy (EASIX-pre) and on the day of transplantation (EASIX-d0). Finally, we analysed the impact of prophylaxis with the endothelium-protective agents pravastatin and ursodeoxycholic acid (UDA) on early bilirubinaemia. Results: Maximum bilirubin levels (days 0-28) were associated with increased risk of overall mortality (OM) and non-relapse mortality (NRM) in patients without SOS/VOD. The optimal bilirubin cut-off for prediction of NRM was found at 3.6 mg/dl (61.6 mM), so that any event of bilirubin≧3.6 mg/dl between days 0 and 28 was defined as early hyperbilirubinemia (EABI). Independent of SOS/VOD, refrGVHD or TAM, EABI predicted OM and NRM in the training and the validation cohort. Although EABI occurred more frequently after anti-thymocyte globulin (ATG) treatment and in patients with myelofibrosis, the effect of EABI on NRM remained stable irrespective of these conditions. EABI was not associated with markers of liver cell and cholangiocyte damage. In contrast, EABI was significantly correlated with pre-transplant serum levels of Angiopoietin-2 as well as increased EASIX-pre and EASIX-d0. Patients receiving prophylaxis with pravastatin and UDA had a reduced risk of death after EABI. Conclusion: EABI is a predictor of NRM and OM independent from SOS/VOD, refrGVHD and TAM. The association of EABI with EASIX, Angiopoietin-2 and statin/UDCA prophylaxis, but not with liver enzymes, suggests a mechanistic role of the endothelium for the pathophysiology of EABI. Table 1: Multivariable Cox-Regression with endpoint non-relapse mortality after d+28. VOD patients were excluded from this analysis. p-values of the training cohort were corrected by bootstrap 1000. Table 1 Disclosures Luft: Neovii: Research Funding; JAZZ: Research Funding. Bullinger:Bayer: Other: Financing of scientific research; Amgen: Honoraria; Astellas: Honoraria; Sanofi: Honoraria; Seattle Genetics: Honoraria; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Daiichi Sankyo: Honoraria; Gilead: Honoraria; Hexal: Honoraria; Janssen: Honoraria; Jazz Pharmaceuticals: Honoraria; Menarini: Honoraria; Novartis: Honoraria; Pfizer: Honoraria; Abbvie: Honoraria. Dreger:Neovii, Riemser: Research Funding; MSD: Membership on an entity's Board of Directors or advisory committees, Other: Sponsoring of Symposia; AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche: Consultancy; AbbVie, Gilead, Novartis, Riemser, Roche: Speakers Bureau.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
活泼溪流完成签到 ,获得积分10
3秒前
余又完成签到 ,获得积分10
3秒前
工艺纯化小天才完成签到 ,获得积分10
19秒前
在路上完成签到 ,获得积分10
20秒前
feiyafei完成签到 ,获得积分10
23秒前
Yi完成签到,获得积分0
31秒前
zjz完成签到 ,获得积分10
33秒前
小西西完成签到,获得积分10
36秒前
今后的应助被阿亮采纳,获得10
43秒前
46秒前
Arvin发布了新的文献求助10
49秒前
詹姆斯哈登完成签到,获得积分0
53秒前
Miya完成签到,获得积分10
55秒前
xurui_s完成签到 ,获得积分10
59秒前
传奇3的应助被竹捷采纳,获得10
1分钟前
烂漫的淇完成签到 ,获得积分10
1分钟前
1分钟前
竹捷发布了新的文献求助10
1分钟前
1分钟前
cczzhh发布了新的文献求助10
1分钟前
昭荃完成签到 ,获得积分0
1分钟前
Lina完成签到 ,获得积分10
1分钟前
回家睡觉完成签到,获得积分10
1分钟前
温馨家园完成签到 ,获得积分0
1分钟前
英姑的应助被科研通管家采纳,获得30
1分钟前
李煜琛完成签到 ,获得积分10
2分钟前
hj完成签到 ,获得积分10
2分钟前
kk完成签到,获得积分10
2分钟前
luoqin完成签到 ,获得积分10
2分钟前
姚芭蕉完成签到 ,获得积分0
3分钟前
my完成签到 ,获得积分10
3分钟前
朴实惜寒完成签到,获得积分10
3分钟前
3分钟前
朴实雨竹完成签到,获得积分10
3分钟前
阿巴完成签到,获得积分10
3分钟前
8D完成签到 ,获得积分10
3分钟前
无限的画板完成签到 ,获得积分10
3分钟前
3分钟前
我爱木棉完成签到 ,获得积分10
3分钟前
颜三路吴彦祖完成签到 ,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195261
求助须知:如何正确求助?哪些是违规求助? 9580992
关于积分的说明 21873160
捐赠科研通 7795344
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484713